Analysts Set DaVita Inc. (NYSE:DVA) Target Price at $199.17

DaVita Inc. (NYSE:DVA) has received a consensus recommendation of “Hold” from the eight brokerages that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have issued a buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $209.00.

DVA has been the subject of several research reports. Zacks Research cut DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Barclays increased their price target on shares of DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a report on Wednesday. Weiss Ratings restated a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. TD Cowen lifted their target price on DaVita from $144.00 to $201.00 and gave the stock a “hold” rating in a research report on Monday, May 11th. Finally, UBS Group raised their price objective on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday.

DaVita Stock Performance

Shares of NYSE DVA traded up $3.03 during mid-day trading on Friday, reaching $232.51. 773,721 shares of the company traded hands, compared to its average volume of 803,036. The company’s fifty day moving average is $204.50 and its two-hundred day moving average is $160.32. DaVita has a fifty-two week low of $101.00 and a fifty-two week high of $239.64. The stock has a market cap of $14.93 billion, a PE ratio of 21.57, a price-to-earnings-growth ratio of 0.76 and a beta of 0.88.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 EPS for the quarter, beating analysts’ consensus estimates of $2.33 by $0.54. The company had revenue of $3.42 billion for the quarter, compared to analyst estimates of $3.36 billion. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company’s quarterly revenue was up 6.0% compared to the same quarter last year. During the same quarter last year, the firm posted $2.00 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Research analysts forecast that DaVita will post 15.07 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Joel Ackerman sold 51,471 shares of the firm’s stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $192.10, for a total transaction of $9,887,579.10. Following the completion of the transaction, the chief financial officer owned 132,434 shares in the company, valued at $25,440,571.40. This trade represents a 27.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kathleen Alyce Waters sold 15,405 shares of the company’s stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the completion of the sale, the insider owned 109,194 shares in the company, valued at $22,756,029.60. This trade represents a 12.36% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On DaVita

A number of large investors have recently bought and sold shares of the business. Doma Perpetual Capital Management LLC boosted its position in shares of DaVita by 23.3% in the 3rd quarter. Doma Perpetual Capital Management LLC now owns 355,574 shares of the company’s stock worth $47,245,000 after purchasing an additional 67,214 shares during the last quarter. Nordea Investment Management AB lifted its stake in DaVita by 18.0% in the fourth quarter. Nordea Investment Management AB now owns 338,192 shares of the company’s stock valued at $38,321,000 after buying an additional 51,607 shares during the period. Munich Reinsurance Co Stock Corp in Munich acquired a new position in DaVita in the third quarter valued at about $5,419,000. WINTON GROUP Ltd bought a new position in DaVita during the third quarter worth about $5,755,000. Finally, Dimensional Fund Advisors LP grew its position in shares of DaVita by 8.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,085,593 shares of the company’s stock worth $144,230,000 after buying an additional 88,061 shares during the period. 90.12% of the stock is currently owned by institutional investors.

DaVita Company Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.